At least one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) has high individual vaccine effectiveness (VE) in preventing invasive pneumococcal disease (IPD) in a paediatric population with suboptimal vaccination coverage, a new study has shown.

Persons with underlying medical conditions are at higher risk of influenza-associated hospitalization.At the recent Malaysian Thoracic Society (MTS) Congress 2017 held in Kuala Lumpur, Professor Pang spoke on the importance of influenza vaccination in patients with chronic respiratory disease and lung cancer, highlighting the benefits of quadrivalent influenza vaccines (QIVs) in providing wider spectrum of protection against influenza types A and B.
Look out for our upcoming Symposium Highlight article to find out more about how FluQuadriTM can help your patients stay healthy.

At least one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) has high individual vaccine effectiveness (VE) in preventing invasive pneumococcal disease (IPD) in a paediatric population with suboptimal vaccination coverage, a new study has shown.